

The Transfemoral TaurusNXT TAVR System Two-Year Results of the NXT-DURA Trial

Wenzhi Pan, MD



TCT®

TRANSCATHETER
CARDIOVASCULAR
THERAPEUTICS®

*Director of Heart Valve Center,
Zhongshan Hospital, Fudan University
Shanghai Institute of Cardiovascular Diseases
China National Clinical Research Center for
Interventional Medicine*

Disclosure of Relevant Financial Relationships

Within the prior 24 months, I have had a relevant financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

Nature of Financial Relationship

Grant/Research Support

Consultant Fees/Honoraria

Individual Stock(s)/Stock Options

Royalties/Patent Beneficiary

Executive Role/Ownership Interest

Other Financial Benefit

Ineligible Company

Hanyu Medical, Shanghai

Hanyu Medical, Shanghai

All relevant financial relationships have been mitigated.



Faculty disclosure information can be found on the app

TaurusNXT Introduction——Product and Technology Iteration

THV leaflet material science improvement



*THV frame, radiopaque markers
& skirt optimization*



TaurusNXT Introduction—Product and Technology Iteration

Non-aldehyde
crosslinking

Decellularization
technology


Pericardial surface
trimming

Identification of pericardial
fiber direction


Low-temperature
vacuum freeze-drying



Non-aldehyde leaflet treatment




Glutaraldehyde
treated surface:
high number of
platelet adhesion &
activation



Non-aldehyde
treated surface:
few number of
platelet adhesion &
activation

Decellularization Technology




Non-GA (Non-Glutaraldehyde):
Significantly fewer residual cells, reduced immunogenic response

Pericardial surface trimming



Irregular fiber
orientation on
surface



Protruding fibers
removed, surface
smoothness
improved

TaurusNXT—3D Steerable Design in Different Cases



Horizontal Heart




Acute Aortic Arch



*Short
Ascending Aorta*



*Dilated
Ascending Aorta*



TaurusNXT Multicenter Clinical Study Data — Patient Baseline

- Prospective, multicenter, single-arm target value study
- A total of 17 centers, 150 patients enrolled and completed 1-year follow-up
- Among them, 52 patients completed 2-year follow-up
- Bicuspid valve patients (~50%) had significantly higher calcium burden and more complex anatomy (wider annular angle, larger STJ dimensions), making procedures more technically demanding

Indicator Mean (SD)	Bicuspid (n=73)	Tricuspid (n=77)	Total (n=150)
Age (years)	74.5±4.2	77.2±4.6	75.9±4.6
Sex (n, %)			
Male	35 (47.9)	43 (55.8)	78 (52.0)
Female	38 (52.1)	34 (44.2)	72 (48.0)
BMI (kg/m ²)	22.7±3.1	23.4±3.9	23.1±3.6
NYHA Class (n, %)			
I	0 (0.0)	0 (0.0)	0 (0.0)
II	18 (24.7)	13 (16.9)	31 (20.7)
III	44 (60.3)	50 (64.9)	94 (62.7)
IV	11 (15.1)	14 (18.2)	25 (16.7)
EQ-5D Score	71.1±12.8	72.3±14.9	71.7±13.9
STS Score (%)	5.2±3.3	5.5±3.1	5.3±3.2
≥Moderate Frailty (%)	36 (49.3)	43 (55.8)	79 (52.7)

Indicator Mean (SD)	Bicuspid (n=73)	Tricuspid (n=77)	Total (n=150)
Aortic Annulus Perimeter (mm)	77.8±8.3	77.1±7.3	77.4±7.8
LVOT Diameter(mm)	25.7±4.6	25.3±3.7	25.5±4.2
Calcium Volume (HU850)*	1003.8±1527.6	584.6±931.9	789.9±1272.6
LM Coronary Ostium Height (mm)	15.4±3.8	13.3±3.2	14.4±3.7
RCA Coronary Ostium Height (mm)	16.7±3.2	16.4±3.2	16.5±3.2
Annular Horizontal Angle (°) *	55.4±9.1	51.4±8.0	53.4±8.8
Ascending aorta diameter (Derived from Perimeter, mm)*	38.3±4.5	35.9±3.9	37.0±4.4
Diameter at Sinotubular junction (Derived from Perimeter, mm)*	31.4±3.5	29.5±3.6	30.4±3.7
Height of Sinotubular junction (mm)*	22.7±4.3	21.3±2.9	22.0±3.7

TaurusNXT Multicenter Clinical Data — Efficacy & Safety

VARC-3 Standardized Definitions for TAVR:

Technical success: 94.7% (142/150)

Device success: 93.3% (140/150)

Valve-in-valve: 4.7% (7/150)


All-cause mortality at 30 days: 2.0% (3/150)

All-cause mortality at 1 year: 5.3% (8/150)





Procedural Outcomes (N = 150) (Based on VARC-3 definitions)	n/N (%)
Intraoperative death	1/150 (0.7%)
Annular rupture	0
Cardiac perforation	1/150 (0.7%)
Coronary obstruction	0
Valve embolization	0
Aortic dissection	0
Access-related vascular events	0
Technical success rate	142/150 (94.7%)
Device success rate	140/150 (93.3%)

Primary Safety Endpoints (Based on VARC-3 definitions)	30 Days (N=150)	1 Year (N=150)	2 Year (N=52*) Follow-up
All-cause mortality	3/150 (2.0%)	8/150 (5.3%)	10
Cardiovascular mortality	1/150 (0.7%)	1/150 (0.7%)	2
All-cause stroke	3/150 (2.0%)	5/148 (3.4%)	5
Disabling stroke	2/150 (1.3%)	3/148 (2.0%)	3
Non-disabling stroke	1/150 (0.7%)	2/148 (1.4%)	2
VARC Type 2–4 Bleeding	6/150 (4.0%)	11/149 (7.4%)	11
Major vascular or structural complication	1/150 (0.68%)	1/148 (0.68%)	1
Stage 3–4 acute kidney injury	1/150 (0.68%)	1/147 (0.68%)	1
≥ Moderate aortic regurgitation	1/146 (0.68%)	2/142 (1.4%)	1
≥ Moderate Intravalvular Leak	0/146 (0.0%)	1/142 (0.7%)	0
≥ Moderate Paravalvular Leak	1/146 (0.68%)	2/142 (1.4%)	1
New permanent pacemaker implantation	10/150 (6.7%)	10/147 (6.8%)	11
Conversion to cardiac surgery	1/150 (0.68%)	1/147 (0.68%)	1
Bioprosthetic valve deterioration	0/150 (0.0%)	0/150 (0.0%)	1
Structural valve deterioration	0/150 (0.0%)	0/150 (0.0%)	0



Echo for Paravalvular Regurgitation — 2Y follow-up





Echo for hemodynamic — 2Y follow-up




NYHA & EQ-5D — 2Y follow-up




Case demonstration





Pre-loading TAV 23mm





20 mm balloon



Summary of NXT-DURA Trial (TaurusNXT)

- *This study is the first to apply non-aldehyde crosslinking “dry-valve” processing technology in an innovative TAVR system. Preliminary data demonstrate good safety and efficacy, with early outcomes superior to those of previous-generation device.*
- *The commissural alignment technique is better aligned with the lifetime management concept of self-expanding valves and facilitates future coronary re-access.*
- *Two-year follow-up results confirmed that the optimized leaflet loading, frame design, and skirt configuration of the TaurusNXT system meet clinical demands, and the overall system performance has been further validated.*
- *Ongoing long-term follow-up will continue to assess the durability and hemodynamic performance of leaflets processed with non-glutaraldehyde crosslinking technology via NXT-Dura trial.*